Online inquiry

IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9699MR)

This product GTTS-WQ9699MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets KLRK1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_007360.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 22914
UniProt ID P26718
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ9699MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8843MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ8584MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ2008MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AGT-181
GTTS-WQ4450MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ7875MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ12657MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ1210MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ11251MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI4736
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW